Back to search

National and Kapodistrian University of Athens

Αναζήτηση ειδικών αυτοαντισωμάτων στη ρευματοειδή αρθρίτιδα με την τεχνική της ανοσοαποτύπωσης (νέες τεχνικές)

Abstract

dc:description

Rheumatoid Arthritis (RA), the most commonly occurring autoimmune disorder, if untreated leads progressively to permanent joint damage and disability. Early therapeutic intervention may prevent progression of joint destruction, however for the initiation of an aggressive treatment more sensitive and specific diagnostic tests are required. In 1987 the American College of Rheumatology (ACR) in addition to clinical criteria, proposed the Rheumatoid Factor (RF) as the only serological diagnostic marker. This marker lacks specificity and has very low sensitivity in the early stages of the disease. In order to meet the need for improved diagnostic and prognostic tests various biomarkers and autoantibodies have being assessed. Among them, only the anti-Cyclic Citrullinated Peptide (anti-CCP) has gained wide acceptance and was included in 2010, in the ACR/EULAR classification criteria for RA. Aim of the study The aim of this study is the detection and measurement of several biomarkers and autoantibodies in Greek patients with RA, the evaluation of their role in the diagnosis of RA and the prediction of the evolution of an inflammatory arthritis to RA. In addition we have investigated their importance in the prognosis of the course of the disease, the response to therapeutic protocols and their use in routine clinical practice, with the formation of an algorithm. Patients and Methods A total of 426 patients were included in the study. Of those 278 (64.4%) were diagnosed as having RA (group A) and 148 (34.6%) suffered from other autoimmune or inflammatory diseases (group B) such as Systemic Lupus Erythematosus (N=31), Mixed Connective Tissue Disease (N=4), Polyarthritis Syndrome (N=47), Seronegative Spondylarthritis (N=36) and Idiopathic Inflammatory Bowel Disease (N=30). Moreover, 32 blood donors were included as healthy controls. As a special category 131 the 47 patients with Polyarthritis Syndrome, 17 (36.2%) of whom developed RA during a six months’ follow up, were studied. The laboratory tests applied in the serum samples of the patients and controls included: 1) the measurement of RF, of C-Reactive Protein (CRP) and of complement factors C3, C4 by nephelometry, 2) the titration of antinuclear (ANA) and anti-double stranded DNA (anti-dsDNA) using indirect immunofluorescence, 3) the detection of autoantibodies to extractable nuclear antigens (anti-ENA) using the method of ELISA and Immunoblotting, and 4) the anti-RA33, anti-CCP2, anti-CCP3.1, anti-MCV antibodies as well as and the RF IgG, IgM and IgA classes, using ELISA. For the statistical analysis of the results the program SPSS 18.0 and STATA 8.0, were used. Results 1. The comparison of group A patients with RA versus group B showed the following results : a) The presence of positive ANA and anti-RA33 antibodies or of abnormal CRP values does not differ significantly between the two groups of patients. b) Anti-ENA antibodies were detected in 47 (16.8%) of 279 samples studied. There was no significant difference in the percentages of positive anti-Ro (SSA) antibodies between the two groups. However the investigation of the specificity of the anti-Ro antibodies for the antigenic epitopes (Ro52, Ro60) showed a higher percentage of anti-Ro52 antibodies in the group A samples in comparison with group B (57.14% vs 21.4%, p= 0.025). c) The percentage of RA patients with positive anti-CCP2, anti-CCP3.1, anti-MCV antibodies and abnormal RF values was significantly higher in group A in comparison to group B patients (p< 0.001). 2. Concerning the criteria of sensitivity and specificity it was shown that anti-CCP2 antibodies have a higher sensitivity (88.1%), whereas anti-MCV antibodies presented a higher specificity (86.3%) compared to the other markers. As a prognostic tool for RA, anti-CCP2 antibodies are a more powerful predictor of disease course (90.4%). 132 3. In assessing the predictive significance of the various diagnostic tests regarding the evolution of the prospective cohort of patients with polyarthritis syndrome which evolved into RA (within a six months period) it was shown that all parameters tested had a prognostic value. However CRP had a significantly lower predictive capacity in comparison to anti-CCP2 (p=0.016) and anti-CCP3.1 (p=0.029), whereas there was no difference in the predictive power of other antibodies. 4. Comparing the values of RF Ig classes, CRP and anti-CCP2 between patients with RA and healthy controls it was shown that anti-CCP2, IgA and IgM RF had a higher prognostic capacity than IgG RF or CRP (p<0.05). Another finding was that the comparison of parameters studied between patients with early RA diagnosis (<2 years) and those with a delayed diagnosis (>2 years), showed no significant difference regarding any of those parameters. 5. The index for disease activity (DAS28) was not shown to be significantly correlated with CRP, RF or anti-CCP2 levels whereas a positive correlation was found with the levels of anti-MCV antibodies (r=0.69, p<0.001). The investigation of the effect of treatment in patients with RA and follow up for a 2 years period showed no significant change in the levels of any of the parameters studied following treatment interventions. Conclusions The anti-CCP2 antibodies have a higher prognostic value for RA patients in comparison to patients with other non RA diseases or healthy subjects. The RF has also a significant predictive power for RA in comparison to non RA diseases and for the progression of polyarthritis syndrome to RA within a six months’ period following diagnosis. Its prognostic capacity is however lower than that of anti-CCP2. Thus it appears that the combination of both markers is of great importance for the diagnosis, prognosis and prediction of the course of RA. Moreover the higher specificity of anti-MCV antibodies for RA compared to non RA diseases and the positive correlation of the levels of the anti-MCV with the changes of DAS28 suggests that they represent the most important marker for assessing disease activity and a useful tool for patient management and treatment decisions.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tsirogianni, Alexandra
  • Τσιρογιάννη, Αλεξάνδρα

Subjects

dc:subject × 18

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/29832

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tsirogianni, Alexandra; Τσιρογιάννη, Αλεξάνδρα. Αναζήτηση ειδικών αυτοαντισωμάτων στη ρευματοειδή αρθρίτιδα με την τεχνική της ανοσοαποτύπωσης (νέες τεχνικές). National and Kapodistrian University of Athens, 2013. http://hdl.handle.net/10442/hedi/29832